Evaluating BAY 3670549 Compared to Placebo for Treating Atrial Fibrillation with Electrical Cardioversion in Adults

What This Trial Is About

Researchers are evaluating the effects of BAY 3670549 in adults with atrial fibrillation who require electrical cardioversion. The study aims to understand how well BAY 3670549 works to restore normal heart rhythm, how safe and tolerable it is, and how the body processes this medicine. Participants will receive either BAY 3670549 or a placebo to compare outcomes. Each participant will receive a single intravenous infusion of BAY 3670549 or a placebo. After this, researchers will observe whether the heart rhythm returns to normal without needing electrical cardioversion. If the heart rhythm does not revert, electrical cardioversion can still be performed as planned. The study measures how many participants convert to normal rhythm and how quickly, as well as any medical issues after treatment and the medicines pharmacokinetics. Participants will be involved for up to two months. During this time, their heart rhythm will be closely monitored, and safety assessments for any adverse events will be conducted up to 48 hours after treatment. Blood samples will be taken to measure the medicine concentration. The primary outcome is the number of participants whose heart rhythm converts to normal within 3 hours without additional treatment, providing important data on the treatments impact on atrial fibrillation.

A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation